Spyre Therapeutics
SYRE
131 hedge funds and large institutions have $1.39B invested in Spyre Therapeutics in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 63 increasing their positions, 20 reducing their positions, and 21 closing their positions.
215% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 20
104% more call options, than puts
Call options by funds: $161K | Put options by funds: $79K
62% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 21
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
10% more funds holding
Funds holding: 119 → 131 (+12)
1.11% more ownership
Funds ownership: 100.89% → 102% (+1.1%)
8% less capital invested
Capital invested by funds: $1.51B → $1.39B (-$118M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$62.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.5M |
| 3 |
JFG
Jefferies Financial Group
New York
|
+$22.3M |
| 4 |
BlackRock
New York
|
+$21.6M |
| 5 |
Goldman Sachs
New York
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$32.8M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$22.9M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$17.6M |
| 4 |
PA
Perceptive Advisors
New York
|
-$8.73M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$7.35M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$29 | -1 | Closed |
|
|
C
152
Covestor
London,
United Kingdom
| – | +$29 | +1 | +33% |
|
SYRE Hedge Fund Activity: Q4 2024 in Review
131 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2024, worth a combined $1.39B — down 7.8% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new SYRE positions and 21 closed out — a net gain of 13 holders — while 63 added to existing stakes and 20 trimmed.
The largest buyer was Driehaus Capital Management, adding an estimated $62.1M. The largest seller was Assenagon Asset Management, cutting an estimated $32.8M.
- 131 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2024, up from 119 in Q3 2024.
- Funds reported $1.39B of Spyre Therapeutics stock for Q4 2024, down 7.8% quarter-over-quarter.
- 34 funds opened new Spyre Therapeutics positions in Q4 2024 and 21 closed out, a net change of +13 holders.
- The largest Spyre Therapeutics buyer in Q4 2024 was Driehaus Capital Management, an estimated $62.1M added.
- The largest Spyre Therapeutics seller in Q4 2024 was Assenagon Asset Management, an estimated $32.8M sold.
Based on aggregated 13F filings for Q4 2024.